NCT04162327View on ClinicalTrials.gov

A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 26, 2019

Primary Completion Date

January 27, 2022

Study Completion Date

June 20, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

IBI315

Patients will receive IBI315 until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.

DRUG

IBI315

Patients will receive IBI315 RP2D until disease progression,intolerability, informed consent withdraw, or otherreasons leading to treatment discontinue.

Trial Locations (1)

Unknown

The 307th Hospital of Chinese People's Liberation Army, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04162327 - A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor | Biotech Hunter | Biotech Hunter